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Introduction
Epstein-Barr virus (EBV) is one of the most successful human 
pathogens, establishing persistent infection in more than 95% 
of adults (1). At the same time, this common γ-herpesvirus is the 
most growth-transforming pathogen in vitro and is associated 
with a variety of B cell lymphomas and epithelial cell carcinomas 
in vivo (2). These amount to approximately 200,000 new cancers 
every year, therefore, EBV constitutes an important target for ther-
apeutic intervention (3). The viral tumorigenic potential is primar-
ily due to the latent EBV infection programs, which express up to 8 
proteins and more than 40 nontranslated RNAs (1). Together with 
these nontranslated RNAs, the 6 EBV nuclear antigens (EBNAs) 
and 2 latent membrane proteins (LMPs) of the latency III program 
transform B cells in vitro into lymphoblastoid cell lines (LCLs) and 
are found in non-Hodgkin’s lymphomas like post-transplantation 
lymphoproliferative disease (PTLD), immunoblastic lympho-
mas, and diffuse large B cell lymphomas (DLBCLs) of immuno-
compromised patients (2). EBNA1, LMP1, and LMP2 expression, 
the more restricted latency II program, is characteristic for EBV- 
associated Hodgkin’s lymphoma, extranodal NK/T cell lympho-
mas, nasopharyngeal carcinoma, and gastric carcinoma. Finally, 
Burkitt’s lymphomas often express only EBNA1 as the sole EBV 
protein. Interestingly, all these EBV latency programs are already 
present in healthy EBV carriers in distinct differentiation stages of 
infected B cells (4), and EBV seems to persist long term in mem-
ory B cells without any viral protein expression (5). The presence 
of growth-transforming latent EBV expression in healthy virus 
carriers and the increased incidence of B cell lymphomas of all 
EBV latency programs in patients with primary immunodeficien-
cies or immune-suppressive HIV coinfection (6, 7) suggest that 
asymptomatic, persistent EBV infection relies on comprehensive 
immune control of all latency patterns.
Indeed, the list of primary immunodeficiencies that predispose 
individuals to EBV-associated diseases identifies cytotoxic lympho-
cytes as the cornerstone of this immune control (6, 8). More specif-
ically, mutations in T cell receptor signaling identify conventional 
αβ T cells and innate NKT as well as γδ T cells as components of this 
immune control (9, 10). Among these, conventional αβ T cells have 
been used therapeutically after expansion with LCLs or defined 
EBV antigens primarily for the treatment of PTLDs (11). While the 
antigen specificities of these clinically efficacious T cell transfers 
often remain undefined, EBNA1 has at least been identified as one 
of the protective EBV antigens by the treatment success seen after 
adoptive transfer of T cell populations that have been selected via 
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Figure 1. Human CD4+ and CD8+ T cell recognition of EBNA1 carrying or encoding vaccine formulations. (A) Structure of humanized EBNA1-Ab fusion 
proteins. (B) Western blot analysis of human αDEC205-EBNA1 Ab under reducing conditions using rat αEBNA1 Ab (clone 1H4). Lane 1 represents heavy-
chain EBNA1 (100 kDa) and lane 2 recombinant truncated EBNA1. (C) Western blot analysis of viral vectors encoding truncated EBNA1, using rat αEBNA1 Ab 
(clone 1H4) 48 hours after infection of HEK293T cells. MVA-E1 carries EBNA1 without the Gly/Ala repeat and runs at approximately 45 kDa (25); MVA-IiE1 
has the additional invariant chain domain. Lenti-E1 carries only EBNA1 from aa 400–641 with an approximate size of 30 kDa. Infection with Adeno–E1-LMP 
also leads to expression of the Gly/Ala repeat–deleted EBNA1 protein, however with additional LMP polyepitopes (26), and migrates at approximately 60 
kDa. Lane 6 represents uninfected HEK293T cells and lane 7 recombinant truncated EBNA1. (D and E) Autologous PBMCs were incubated with medium for 
4 hours with 1 μg/ml EBNA1 fused to an Ab against the indicated receptors, or for 1 hour with the cognate peptides for the respective T cell clones. Cocul-
ture with (D) EBNA1-specific CD4+ T cell clones, with cognate epitope NLR and SNP shown in the gray bars, and (E) EBNA1-specific CD8+ T cell clones, with 
cognate epitope HPV shown in the white bars. T cell activity was measured by IFN-γ release into the supernatant. IFN-γ signal is shown as a percentage 
of the peptide control. Data are shown as the mean ± SD of at least 2 independent experiments. ***P < 0.005 versus unspecific CD207-targeting; 1-way 
ANOVA with Bonferroni’s pre-test . (F and G) Autologous PBMCs were infected with DMSO control, MVA-EBNA1, MVA-liEBNA1, or Adeno–EBNA1-LMP at a 
MOI of 10 for 48 hours and with Lenti-EBNA1 or Lenti-IiEBNA1 for 96 hours. Coculture with (F) EBNA1-specific CD4+ T cell clones, with cognate epitope NLR 
and SNP shown in the light gray bars and cognate epitope AEG shown in the dark gray bars, and (G) EBNA1-specific CD8+ T cell clones, with cognate epitope 
HPV shown in the white bars. T cell activity was determined as in D and E. Data are shown as the mean ± SD of 2 independent experiments. **P < 0.01 and 
***P < 0.005; 1-way ANOVA plus Bonferroni’s pre-test.
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detected at an apparent weight of approximately 100 kDa (Fig-
ure 1B, Supplemental Figure 1B; supplemental material available 
online with this article; https://doi.org/10.1172/JCI125364DS1). 
Binding specificity after cloning was confirmed through a com-
petitive binding assay, in which binding of the original hybridoma 
Abs on a target cell could be overcome by prior incubation with the 
engineered Ab constructs (Supplemental Figure 1A). EBNA1-Abs 
for all 8 receptors and for DEC205 were produced and maintained 
their receptor binding activity.
To assess the MHC class I and II presentation of these recep-
tor-targeted EBNA1-Abs, we generated EBNA1-specific CD4+ and 
CD8+ T cell clones from healthy EBV carriers. We used CD4+ T cell 
clones recognizing different epitopes, designated SNP restricted 
through HLA-DR51, NLR restricted through HLA-DR1, and AEG 
restricted through HLA-DQ2/3. In addition, we used established 
EBNA1-specific CD8+ T cell clones that were specific for the HPV 
epitope restricted through HLA-B35, because this specificity can 
be readily cloned from HLA-B35–positive EBV carriers. PBMCs 
were incubated with 1 μM EBNA1 fusion Abs for 4 hours and 
then cocultured with autologous T cell clones. IFN-γ secretion of 
CD4+ and CD8+ T cells was very low when cocultured with untar-
geted PBMCs. An EBNA1-Ab fusion protein targeted to langerin 
(CD207), which is not expressed on PBMCs, slightly induced IFN-γ 
production, suggesting that alternative antigen uptake mecha-
nisms may contribute to the background activation of T cells in 
this experimental setting. Targeting of DEC205 and CD40 sig-
nificantly enhanced CD4+ T cell activation to approximately 60% 
of the signal obtained from peptide-pulsed PBMCs that served as 
a positive control (Figure 1D). Antigen delivery through DEC205 
also yielded one of the highest responses in CD8+ T cells, and only 
BDCA3 targeting exceeded this and led to significant CD8+ T cell 
activation, with secreted IFN-γ levels that were approximately 8% 
of those in the positive control (Figure 1E). Therefore, we identi-
fied BDCA3 targeting as the strongest receptor-targeting strategy 
for cross-presentation on MHC class I molecules. However, anti-
gen targeting to BDCA3 did not significantly enhance cross-pre-
sentation in comparison with DEC205-directed antigen delivery.
Viral vectors have been shown to induce higher CD8+ T cell 
activation, therefore, we complemented our panel of EBNA1-
Ab fusion proteins with viral vectors encoding for EBNA1 or 
invariant chain EBNA1, namely MVAs (MVA-E1 and MVA-
IiE1), lentiviruses (Lenti-E1 and Lenti-IiE1), and an adeno-
virus 5 (Adeno–E1-LMP). PBMCs were incubated with MVAs 
and adenoviruses for 24 hours before coculturing with T cell 
clones and with lentiviruses for 96 hours, given their slower 
infection kinetics. First, we assessed EBNA1-specific CD4+ T 
cell activation and found that all tested viral vectors triggered a 
response. Notably, the addition of the invariant chain to EBNA1 
in MVA-IiE1 elicited higher IFN-γ production. Moreover, we 
assessed the responses of another CD4+ T cell clone specific for 
the AEG peptide and detected strikingly high activation levels 
after coculture with Adeno–E1-LMP–infected PBMCs, which 
reached approximately 400% of the peptide-pulsed positive 
control (Figure 1F). CD8+ T cell activation by Adeno–E1-LMP 
was as strong as the peptide-loaded positive control. Surpris-
ingly, the MVA-IiE1 not only led to higher CD4+ T cell activa-
tion but to CD8+ T cell activation as well, suggesting that the 
cytokine production in response to this latent EBV antigen (12). 
Furthermore, EBNA1 is consistently recognized at least by CD4+ T 
cells in nearly all healthy EBV carriers (13, 14), and both EBNA1-spe-
cific CD4+ and CD8+ T cells are able to target EBV-transformed B 
cells (15–17). For the direct recognition of EBV-transformed B cells 
by EBNA1-specific CD4+ T cells, it has been demonstrated that this 
antigen is intracellularly processed for MHC class II presentation 
via macroautophagy (18, 19). Finally, EBNA1 is also an attractive 
target, because it is the sole EBV protein that is expressed in all 
EBV-associated malignancies and can therefore serve as a viral 
tumor antigen to be targeted by passive and active vaccination 
against EBV-associated diseases (20). Thus, we aimed to identify 
a potent vaccine formulation to prime EBNA1-specific CD4+ and 
CD8+ T cell responses. Our findings suggest that heterologous 
prime-boost vaccinations for CD4+ T cell priming by either recom-
binant Abs that target EBNA1 to DCs using DEC205 (αDEC-E1) or 
MVA-encoding EBNA1 (MVA-E1) need to be combined with CD8+ 
T cell priming by EBNA1-encoding adenovirus (Adeno–E1-LMP) to 
establish efficient long-term immune control of EBNA1-expressing 
lymphomas. This immune control relied on both CD4+ and CD8+ 
T cell populations, which reached the highest cytotoxic CD8+ T 
cell frequencies and maintained a broad repertoire of CD8+ T cell 
effector functions only in the presence of CD4+ T cell help. We 
propose that our most successful prime-boost regimens (αDEC-E1 
plus Adeno–E1-LMP or Adeno–E1-LMP plus MVA-IiE1) should be 
further developed for clinical application.
Results
Human CD4+ and CD8+ T cell recognition of EBNA1 carrying or 
encoding vaccine formulations. It has been previously demonstrat-
ed that targeting antigens to the type I transmembrane multilectin 
receptor DEC205 that is preferentially expressed on convention-
al type 1 DCs (cDC1s) leads to prominent CD4+ T cell responses 
but has only a subtle effect on CD8+ T cell induction in vitro and 
in vivo (21–24). To potentially identify a more suitable receptor 
for enhanced antigen delivery to both MHC class I and II path-
ways, we constructed fusion proteins of EBNA1 and Abs directed 
at 9 other receptors with different internalization kinetics and 
expressed by similar or different myeloid cell subsets (as indicat-
ed in parentheses): BDCA3 (cDC1s), CD206 (monocytes), CD207 
(Langerhans cells and dermal cDC1s), CD209 (DCs), CD40 (all 
antigen-presenting cells), HLA-DR (all antigen-presenting cells), 
CD1c (cDC2s), and CD11c (in blood, primarily DCs).
In the first step toward the generation of EBNA1-Ab fusion 
proteins, the variable region sequences of the chosen Abs were 
selected from mouse hybridoma cell lines. The sequenced vari-
able regions of the heavy and light chains were synthesized into 
HEK expression vectors, and the sequence coding for EBNA1 aa 
400–641 was added to the heavy chain vector.
The EBNA1-Ab fusion proteins that were produced consisted 
of human constant regions including κ light chain and IgG1 heavy 
chain, the EBNA1400–641 sequence, and a His-tag for easier detec-
tion and purification (Figure 1A). The fusion Abs only differ in 
their variable regions. EBNA1-Ab fusion proteins were produced 
in stable infected human embryonic kidney 293 T cell (HEK293T 
cell) lines, and their purification was monitored by SDS-PAGE 
and EBNA1 Western blotting, with which the heavy chain can be 
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infections to induce EBNA1-specific T cell responses, we devel-
oped homologous and heterologous prime-boost vaccinations in 
a human DEC205-Tg (huDEC205-Tg) C57BL/6 mouse model. 
We focused on DEC205 targeting, as it elicited one of the highest 
CD4+ and CD8+ T cell responses in our in vitro experiments, and 
because targeting to other receptors did not result in substantially 
improved cross-presentation of EBNA1 on MHC class I molecules 
for CD8+ T cell stimulation. We combined DEC205 targeting of 
antigen with the most promising viral vectors, namely, Adeno–
E1-LMP and MVA-IiE1, as well as Lenti-IiE1, given that lentiviral 
vectors have been extensively explored in virus-based therapies 
(reviewed in ref. 27). In both the heterologous and homologous 
vaccine regimens, boosting vaccines were injected 4 weeks after 
the priming vaccines. In comparison, administration of Adeno–
E1-LMP prime plus MVA-IiE1 boost was recently introduced as a 
promising vaccination approach for malaria (28). CD4+ and CD8+ 
T cell responses toward the EBNA1 antigen were analyzed using 
intracellular cytokine staining (ICS) of IFN-γ after restimulation 
of splenic cells for 5 hours with an EBNA1 peptide library that 
covered aa 400–641 (Figure 2A and Supplemental Figure 2A). 
The highest CD4+ T cell response was induced by the homolo-
gous immunization with αDEC-E1 and poly(I:C) as an adjuvant 
(Figure 2B). Adeno–E1-LMP, Lenti-IiE1, and MVA-IiE1 only elic-
ited mild or no CD4+ T cell responses in vivo, which improved 
markedly when these viral vectors were preceded by αDEC-E1. 
We also observed an increase in the frequency of IFN-γ–secreting 
CD4+ T cells after heterologous prime-boost with Adeno–E1-LMP 
and MVA-IiE1 compared with either vector alone. However, 
the effect of vaccine combinations on the CD8+ T cell compart-
ment was much more striking. We detected a strong and signif-
icant increase in CD8+ T cell responses after vaccination with 
αDEC-E1 followed by adenoviral or lentiviral vectors, with only 
Lenti-IiE1 being able to prime EBNA1-specific CD8+ T cells on its 
own. MVA-IiE1 alone or in combination with receptor targeting 
did not induce IFN-γ–secreting CD8+ T cells, whose frequency 
was significantly enhanced, however, after priming with Adeno–
E1-LMP (Figure 2B). Hence, it can be concluded that heterolo-
gous prime-boost vaccination increases the level of EBNA1-spe-
cific CD8+ T cell responses in huDEC205-Tg mice in comparison 
with homologous prime-boost vaccination. Of note, using IFN-γ 
ELISPOT and restimulation of splenic cells after vaccination with 
all single peptides of the EBNA1 peptide mix, we showed that the 
EBNA1-specific T cell responses were distributed quite evenly 
over the whole length of the EBNA1 protein, with stronger pep-
tide recognition in 4 clusters (Supplemental Figure 2B). In addi-
tion to IFN-γ, other Th1 cytokines such as TNF-α and IL-2 have 
been shown to play a role in antiviral and/or antitumor immuni-
ty (29, 30). To assess the number of polyfunctional EBNA1-spe-
cific T cells after different vaccination schemes, we analyzed 
their cytokine expression profile by ICS. In general, CD4+ T cells 
showed a more pronounced polyfunctional phenotype than did 
CD8+ T cells. DEC205 targeting led to the highest percentage of 
CD4+ T cells that produced either 2 or 3 of the above-mentioned 
cytokines, irrespective of the vaccination strategy (Figure 2C). 
Viral vectors induced a high number of CD4+ T cells that pro-
duced IFN-γ, TNF-α, or IL-2 alone (Supplemental Figure 2C). 
Generally, CD8+ T cells followed the same trend. After Adeno–
MHC class I presentation of EBNA1 benefits from the invariant 
chain fusion construct. Even after 96 hours of incubation, the 
tested lentiviruses did not induce an EBNA1-specific CD8+ T 
cell response (Figure 1G). Thus, adenoviral delivery of EBNA1 
allowed for 10-fold higher CD8+ T cell stimulation than did any 
receptor targeting of EBNA1, and both MVA and adenoviruses 
stimulated EBNA1-specific CD4+ T cells, similar to what was 
observed with receptor targeting by fusion Abs.
We also performed Western blotting to analyze EBNA1 
expression in virus-infected cells. The infection of HEK293T cells 
by MVA-E1, Lenti-E1, and Lenti-IiE1 yielded high expression of 
EBNA1, whereas the EBNA1 signal after MVA-IiE1 and Adeno–
E1-LMP infection was very low (Figure 1C). Since the constructs 
varied, the EBNA1 band was visible at different molecular weights. 
MVA-E1 carries EBNA1 without the Gly/Ala repeat and runs at 
approximately 45 kDa (25), and MVA-IiE1 migrates more slowly 
(at a higher molecular weight) because of the additional invariant 
chain protein. Lenti-E1 carries only the most immunogenic part of 
EBNA1, the C-terminus from aa 400–641, with an approximate 
size of 30 kDa. Infection with Adeno–E1-LMP also leads to expres-
sion of the Gly/Ala repeat–deleted EBNA1 protein, however, with 
additional LMP polyepitopes (26), it migrates at approximately 
60 kDa. The analysis of virus-infected PBMCs showed a slight-
ly different trend: MVA-IiE1 and MVA-E1 led to strong EBNA1 
expression, whereas even after 96 hours of infection, Lenti-IiE1 
only yielded low expression of EBNA1 (Supplemental Figure 1, C 
and D). The lower-molecular-weight bands, seen after MVA-IiE1 
and MVA-E1 infection of PBMCs, were possibly degraded EBNA1 
protein. The high activation of T cell clones after coculture with 
Adeno–E1-LMP–infected PBMCs could not be directly correlated 
with high EBNA1 expression in infected cells.
Comprehensive priming of mouse CD4+ and CD8+ T cell responses 
against EBNA1 by heterologous vaccination. To investigate the dif-
ferent capacities of receptor-targeting strategies and viral vector 
Figure 2. Comprehensive priming of mouse CD4+ and CD8+ T cell 
responses against EBNA1 by heterologous vaccination in huDEC205-Tg 
mice. huDEC205-Tg mice were immunized with different combinations 
of vaccines for the prime and the boost, which were scheduled 4 weeks 
apart. Mice were sacrificed 2 weeks after the boost. Bulk splenocytes were 
harvested and stimulated either with 1 μg/ml EBNA1 or control HCMV 
pp65 peptide pools. (A) Representative dot plots of ICS of restimulated 
splenocytes, gated for CD4 or CD8 expression and IFN-γ. One dot plot is 
shown for the PBS-treated and vaccination groups αDEC-E1 plus αDEC-E1, 
αDEC-E1 plus Lenti-IiE1, αDEC-E1 plus Adeno–E1-LMP, αDEC-E1 plus MVA-
IiE1, and Adeno–E1-LMP plus MVA-IiE1 as representative examples for the 
data summarized in B. (B) Frequency of IFN-γ+CD4+ and IFN-γ+CD8+ cells 
from total splenocytes. Data are shown as the mean ± SEM from 4 inde-
pendent experiments with at least 3 mice per group. *P < 0.05, **P < 0.01, 
***P < 0.001, and ****P < 0.0001 versus PBS-treated mice; Kruskal-Wallis 
test with Dunn’s multiple comparison post test. (C) Cytokine profile of 
total splenic CD4+ or CD8+ T cells in mice vaccinated with αDEC-E1 plus 
αDEC-E1, αDEC-E1 plus Lenti-IiE1, αDEC-E1 plus Adeno–E1-LMP, αDEC-E1 
plus MVA-IiE1, or Adeno–E1-LMP plus MVA-IiE1. Pie charts show the mean 
of percentage of each cytokine-secreting subset. (D) Serum obtained 
from mice from prime-boost experiments was analyzed for α–EBNA1 IgG 
by ELISA. Each data point represents 1 individually analyzed mouse. A 
negative control that contained no serum was included. **P < 0.01, versus 
PBS-treated mice; Kruskal-Wallis test with Dunn’s multiple comparisons 
post test. Error bars indicate the SEM.
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E1-LMP vaccination, we observed polyfunctionality, which was 
slightly decreased after combination with αDEC-E1 priming. 
Also, αDEC-E1 plus MVA-IiE1 vaccination led to polyfunctional 
CD8+ T cell responses, which was not observed with homologous 
MVA-IiE1 vaccination alone. Interestingly, MVA-IiE1 vaccination 
led to the highest number of IL-2–secreting CD8+ T cells, inde-
pendent of combination with αDEC-E1 or Adeno–E1-LMP. Most 
successful vaccines induce not only robust T cell responses but 
also functional Ab responses. Therefore, we investigated whether 
the different homologous and heterologous vaccination schemes 
lead to αEBNA1 IgG Ab titers in the serum of vaccinated animals. 
In line with the strong and diverse CD4+ T cell responses, the 
homologous prime-boost regimen with αDEC-E1 led to the high-
est αEBNA1 IgG Ab titers (Figure 2D). Among the investigated 
viral vectors studied, only Lenti-IiE1 led to high αEBNA1 IgG Ab 
titers, which correlated with the CD4+ T cell responses that were 
induced by Lenti-IiE1. As soon as αDEC-E1 was applied as a prim-
ing vaccine, αEBNA1 IgG Ab titers were also found to be elevated 
Figure 3. Persistent and potent 
EBNA1-specific CD8+ T cell respons-
es upon comprehensive CD4+ and 
CD8+ T cell priming by heterologous 
vaccination. HuDEC205-Tg mice were 
immunized with different combinations 
of vaccines for the prime and the boost, 
which were scheduled 4 weeks apart. 
Mice were sacrificed 2 weeks (A–C) or 21 
weeks (E–G) after the boost. Bulk sple-
nocytes were harvested and stimulated 
either with 1 μg/ml EBNA1 or control 
HCMV pp65 peptide pools. IFN-γ 
production by CD4+ (A and E) or CD8+ 
(B and F) T cells was monitored by ICS. 
α–EBNA1 IgG titers were determined 
by ELISA (C and G). Each data point 
represents 1 individual mouse. Data 
are shown as the mean ± SEM from 
3 independent experiments (inverse 
regimen) or 1 long-term experiment.  
*P < 0.05, **P < 0.01, and ***P < 0.001; 
Kruskal-Wallis with Dunn’s multiple 
comparisons post test. (D) Mice from 
1 long-term experiment were observed 
up to week 21 after the boost. Blood 
was withdrawn at weeks 7, 11, 15, and 21 
after the boost. PBMCs were restimu-
lated with 1 μg/ml EBNA1 peptide pool 
after vaccination. IFN-γ production was 
monitored by ICS in CD8+ cells. Data are 
shown as the mean ± SEM. *P < 0.05 
versus PBS-treated mice; 2-way ANOVA 
with Tukey’s multiple comparisons test.
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Figure 4. Protection from EBNA1-expressing EL4 lymphoma challenge by heterologous prime-boost vaccination in huDEC205-Tg mice. (A) hHuDEC205-Tg mice 
were immunized with different combinations of vaccines for the prime and the boost, which were scheduled 10 days apart. Mice were s.c. challenged with 2 × 105 
EBNA1-expressing EL4 cells (EL4-E1) either 14 days after the boost in a prophylactic setting (B, C, and D) or 1 to 7 days before the prime vaccination in a therapeutic 
setting (E, F, and G). Mice were monitored every second day, weight was measured, and tumor size was analyzed by caliper. Mice were sacrificed when the tumor 
reached 15 mm or more in diameter. (B and E) The tumor volume was calculated using the formula A2 × B × 0.52, where A is the shortest diameter perpendicular to 
the longest diameter, and B is the longest diameter. The mean tumor volume plus the SD of 3 independent experiments with at least 3 mice per group is shown. 
*P < 0.05 versus PBS-treated mice; 2-way ANOVA with Tukey’s multiple comparisons test. (C and F) The percentage survival from 3 independent experiments with 
at least 3 mice per group is shown. *P < 0.05 and ***P < 0.001; Mantel-Cox test. (D and G) At sacrifice, bulk single-cell suspensions of LN cells were harvested and 
analyzed by EBNA1 qPCR from representative prophylactic (D) and therapeutic (G) EL4-E1 tumor challenges. Abundance of the EBNA1 gene was normalized to the 
UBC gene as the tumor load. A tumor-load cutoff of 0.005 or greater was set. The percentage of mice per condition with and without tumor burden in the LNs is 
depicted. Statistical analysis was done by 2-way ANOVA with Tukey’s multiple comparisons test using the quantitation cycle (cq) value of the qPCR.
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a negative control (Figure 3, E and F). The overall CD4+ as well 
as CD8+ T cell responses were lower than those in the short-term 
experiments, but EBNA1-specific CD4+ T cell responses were still 
detectable at the time of sacrifice but at similar levels across all 
immunization groups (Figure 3E). After αDEC-E1 plus Adeno– 
E1-LMP immunization, we detected  higher percentages of 
EBNA1-specific CD4+ T cells in comparison with percentages seen 
with inverse Adeno–E1-LMP plus αDEC-E1 and Adeno–E1-LMP 
plus MVA-IiE1 vaccination. Mice in the heterologous prime-boost 
vaccination regimens showed slightly higher antigen-specific 
CD8+ T cell responses than did mice given viral vector vaccines 
alone (Figure 3F). Interestingly, even 21 weeks after the boost, 
the deficit in EBNA1-specific CD8+ T cell responses, comparing 
αDEC-E1 plus Adeno–E1-LMP with inverse prime-boost Adeno–
E1-LMP plus αDEC-E1, was significant. We also assessed B cell 
responses toward EBNA1 at this time point and found significantly 
higher αEBNA1 Ab titers only in mice vaccinated with αDEC-E1 
compared with titers detected in the nonvaccinated (PBS-treat-
ed) mice (Figure 3G). αDEC-E1 plus Adeno–E1-LMP and Adeno–
E1-LMP plus MVA-IiE1 regimens mostly produced similar results, 
except with respect to the longevity of the CD8+ T cell response. 
This CD8+ T cell lifespan was further increased in animals vacci-
nated with Adeno–E1-LMP plus MVA-IiE1 compared with animals 
vaccinated with αDEC-E1 plus Adeno–E1-LMP, with the latter 
group having a more diverse cytokine profile within the CD8+ T 
cell population. Hence, we chose αDEC-E1 plus Adeno–E1-LMP 
and Adeno–E1-LMP plus MVA-IiE1 for further studies.
Protection from EBNA1-expressing EL4 lymphoma challenge 
by heterologous vaccination. To evaluate the therapeutic effect of 
the most potent heterologous prime-boost vaccinations, name-
ly, αDEC-E1 plus Adeno–E1-LMP and Adeno–E1-LMP plus 
MVA-IiE1, we developed an EBNA1+ model tumor. EL4, a T cell 
lymphoma cell line, was infected with Lenti-EBNA1-GFP. GFP+ 
lymphoma cells were enriched by FACS and assessed for EBNA1 
expression by Western blotting and IHC (Supplemental Figure 3, 
A and D). We performed histological analysis of untreated EL4-E1 
tumors and observed positive staining for CD4 and FoxP3. Only 
a few tumor-infiltrating CD8+ T cells were detected (Supplemen-
tal Figure 3B). Mice were vaccinated with either αDEC-E1 plus 
Adeno–E1-LMP or Adeno–E1-LMP plus MVA-IiE1 or homolo-
gously with αDEC-E1 or Adeno–E1-LMP as a comparison. Also, 1 
inverse prime-boost vaccination, Adeno–E1-LMP plus αDEC-E1, 
was included to assess the importance of the order of vaccines in 
prime-boost regimens. Mice were challenged with EL4-E1 tumor 
cells on 2 different schedules and then given either prophylactic 
or therapeutic vaccination (Figure 4A). In the prophylactic vacci-
nation group, 2 weeks after the boost, mice were injected s.c. with 
2 × 105 EL4-E1 cells/mouse. In the therapeutic vaccination group, 
mice were challenged on day 0, and immunization followed with-
in 1 to 7 days. Tumor burden was analyzed every second day by 
caliper measurement. In the challenge after αDEC-E1 plus Adeno– 
E1-LMP or Adeno–E1-LMP plus MVA-IiE1 prophylactic vacci-
nation, 11 of 13 mice showed complete EL4-E1 tumor rejection 
(Figure 4B). The survival rate of these mice was increased from 
10% to 100% (Figure 4C). Homologous vaccinations led to slower 
and decreased tumor growth, which was comparable to the tumor 
growth observed in the inverse prime-boost group. The spread 
along with the other viral vectors Adeno–E1-LMP and MVA-IiE1. 
Surprisingly, the combination of Adeno–E1-LMP and MVA-IiE1 
also induced good Ab responses toward EBNA1. However, these 
Ab responses against the nuclear EBNA1 antigen probably do not 
contribute to protection but rather indicate the magnitude of the 
corresponding CD4+ T cell responses. These studies indicated 
that αDEC-E1 plus Adeno–E1-LMP1, αDEC-E1 plus Lenti-IiE1, 
and Adeno–E1-LMP plus MVA-IiE1 elicit the highest balanced 
CD4+ and CD8+ T cell responses against EBNA1. Lentiviruses can 
possibly cause harm in the host because of gene dysregulation that 
can occur after lentiviral genome insertion into the host genome. 
Because αDEC-E1 plus Lenti-IiE1 did not confer a clear advan-
tage compared with αDEC-E1 plus Adeno–E1-LMP1 vaccination, 
we focused our vaccination strategies on Adeno–E1-LMP1.
Persistent and potent EBNA1-specific CD8+ T cell responses upon 
comprehensive CD4+ and CD8+ T cell priming by heterologous vacci-
nation. It has been shown that CD4+ T cell help is not only needed 
for CD8+ T cell priming but also for maintaining protective CD8+ T 
cell memory. CD4+ T cells have been shown to assist in the priming 
of protective CD8+ T cell responses by CD40L- and CD40-medi-
ated DC maturation (31–33) and to maintain CD8+ T cell function 
via IL-2 and IL-21 (34, 35). Therefore, antigen-specific CD4+ T 
cell responses might augment priming of CD8+ T cells against the 
same antigen. In order to investigate the effect of CD4+ T cell help 
by αDEC-E1 priming before vaccination with viral vectors, the 
heterologous prime-boost immunization schemes were inversed. 
In the inverse heterologous prime-boost vaccination, the viral vec-
tor Adeno–E1-LMP was used as a priming vaccine and αDEC-E1 
as a boost. Comparison of standard versus inverse heterologous 
prime-boost regimens showed that priming with αDEC-E1 aug-
mented CD8+ T cell priming induced by Adeno–E1-LMP (Figure 
3B). The inversion led to significantly lower EBNA1-specific CD8+ 
T cell responses. In contrast, CD4+ T cell responses as well as the 
amount of αEBNA1 IgG in the serum of vaccinated mice were not 
affected by the inversion (Figure 3, A and C). The sole effect on 
CD8+ T cell responses supports our hypothesis that the CD8+ T cell 
priming and maintenance during our heterologous prime-boost 
vaccination is dependent on CD4+ T cell help.
To assess how long the vaccinated mice were capable of elic-
iting T cell responses to EBNA1, the mice were observed until 
week 21 after the boost. PBMCs were collected 2 weeks after the 
boost and then approximately once a month to test for restimu-
lation capacity after an EBNA1 peptide pulse in ICS (Figure 3D). 
We found that CD4+ T cell responses were generally low in the 
periphery but were most prominent after αDEC-E1 vaccination 
(data not shown). CD8+ T cell responses peaked in week 2 after 
the boost. The heterologous prime-boost vaccines Adeno–E1-LMP 
plus MVA-IiE1 and αDEC-E1 plus Adeno–E1-LMP induced the 
highest EBNA1-specific CD8+ T cell responses in the blood, with 
the latter remaining consistently high over a 15-week period. This 
long-term immunity was not seen after αDEC-E1 plus Lenti-IiE1, 
which may be partly due to the lower ability of the Lenti-IiE1 
boosting vaccine to induce CD4+ T cell help (data not shown). 
To assess the long-term EBNA1-specific immune responses in 
greater detail, all mice were sacrificed 21 weeks after the boost. 
Splenic cells were restimulated with an EBNA1 peptide library and 
a human cytomegalovirus pp65 (HCMV pp65) peptide library as 
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Figure 5. Dependence on CD4+ and CD8+ T cell populations for protection from EL4-E1 challenge after heterologous vaccination. (A) huDEC205-Tg 
mice were immunized with different combinations of vaccines for the prime and boost scheduled 10 days apart. Before the prime and before the boost, 
mice were depleted with injections of αCD4 or αCD8 Ab on 3 consecutive days. Mice were challenged with 2 × 105 EL4-E1 cells s.c. 14 days after the 
boost. Mice were monitored every second day, weight was measured, and tumor size was analyzed by caliper. (B) Tumor growth was determined every 
second to third day. Tumor volume was calculated by the formula: A2 × B × 0.52. The mean tumor volume plus the SD of the experiment with 6 mice 
per group is shown. *P < 0.05 and **P < 0.01; 2-way ANOVA and Tukey’s multiple comparisons test. (C) Mice were sacrificed when the tumor reached 
15 mm or more in diameter. The percentage survival from 1 experiment with 6 mice per group is shown. *P < 0.05 and **P < 0.005; Mantel-Cox test. 
(D) At the point of sacrifice, bulk splenocytes were harvested and stimulated either with 1 μg/ml EBNA1 or control HCMV pp65 peptide pool. IFN-y 
production was monitored by ICS in CD8+ gated cells. The mean ± SEM from 1 experiment with 6 mice per group is shown. P = 0.05; Kruskal-Wallis with 
Dunn’s multiple comparisons post test. (E) At sacrifice, bulk single-cell suspensions of cells from LNs were harvested and analyzed by EBNA1 qPCR. 
Abundance of EBNA1 gene was normalized to the UBC gene. Data are shown as the mean ± SD from experiments with 6 mice per group. *P < 0.05; 
statistical analysis was done by 2-way ANOVA and Tukey’s multiple comparisons test using the cq value of the qPCR.
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the survival of depleted versus nondepleted mice, we noted a 
trend toward early dropouts in the tumor cell–challenged and 
CD4+ or CD8+ T cell–depleted mice without vaccination (Figure 
5C). Following CD4+ T cell depletion, both heterologous vaccines 
lost the ability to control EL4-E1 tumor growth. Loss of tumor 
growth control, to a lesser extent, was also observed in the CD8+ 
T cell–depleted vaccinated animals. Moreover, the survival of T 
cell–depleted vaccinated mice was drastically diminished in com-
parison with the survival of nondepleted vaccinated mice. Even 
though vaccinated and CD8+ T cell–depleted mice still maintained 
some immune control of tumor growth (Figure 5B), their survival 
was significantly reduced (Figure 5C), possibly due to immunopa-
thology of more strongly stimulated EBNA1-specific CD4+ T cells. 
In order to assess whether CD4+ T cell help is required for com-
prehensive CD8+ T cell priming and maintenance, splenic cells 
were restimulated with the EBNA1 peptide library at sacrifice, and 
CD8+ T cell responses were measured by ICS for IFN-γ secretion 
(Figure 5D). We observed a diminished EBNA1-specific CD8+ T 
cell response after CD4+ T cell depletion in mice vaccinated with 
αDEC-E1 plus Adeno–E1-LMP in comparison with the mice in the 
nondepleted group. This trend was also visible, but not significant, 
in mice in the Adeno–E1-LMP plus MVA-IiE1 vaccination group. 
In addition, we found abrogated αEBNA1 Ab titer in the heterol-
ogously vaccinated mice after CD4+ T cell depletion (Supplemen-
tal Figure 3E). To understand the importance of peripheral T cell 
immunity for EL4-E1 metastasis, LNs were taken and analyzed 
for EBNA1 DNA content by quantitative PCR (qPCR) normalized 
to ubiquitin C (UBC). In general, all tested vaccinations reduced 
the number of mice with LN metastasis. However, this control was 
strongly decreased upon CD8+ T cell depletion in mice vaccinated 
with αDEC-E1 plus Adeno–E1-LMP, whereas depletion of both T 
cell subsets in the Adeno–E1-LMP plus MVA-IiE1 group led to a 
higher percentage of mice with LN metastasis (Figure 5E). Alto-
gether, this suggests that after heterologous prime-boost vaccina-
tion, the main EL4-E1 tumor site is controlled primarily by CD4+ 
T cell–dependent processes, whereas control over the spreading 
of tumor cells toward other organs mainly relies on peripher-
al EBNA1-specific CD8+ T cell immunity. We also analyzed the 
amount of EBNA1 DNA in the isolated tumors after the depletion 
experiments and found that relapsing tumors after successful 
treatment with heterologous prime-boost vaccinations such as 
αDEC-E1 plus Adeno–E1-LMP and Adeno–E1-LMP plus MVA-IiE1 
lost the EBNA1 DNA almost completely (Supplemental Figure 3F). 
This might have occurred as a result of the strategy of generating 
EL4-E1 by sorting for EBNA1+GFP+ cells after lentiviral transduc-
tion, which yielded purities of only approximately 98%. The neg-
ative selection pressure on EBNA1+ EL4 cells might be very high 
during the vaccinations, with the result that the remaining 2% 
EBNA1– EL4 cells survive and relapse. These studies demonstrate 
a dependence on both CD4+ and CD8+ T cells for protection from 
EL4-E1 tumor challenge after heterologous vaccination.
Protection from EBNA1-induced B cell lymphoma challenge by 
heterologous vaccination. To test the most promising heterologous 
prime-boost vaccinations against a tumor model that more close-
ly resembles human EBV–associated malignancies, especially 
c-Myc–driven Burkitt’s lymphoma, we used EBNA1-induced B 
lymphoma cells on a C57BL/6 background  (36). These EBNA1+ 
of EL4-E1 tumor cells into lymph nodes (LNs) was significantly 
decreased only with Adeno–E1-LMP plus MVA-IiE1 vaccination 
(Figure 4D). In mice in the therapeutic vaccination group, EL4-E1 
tumor growth was significantly decreased and slowed down with 
αDEC-E1 plus Adeno–E1-LMP and Adeno–E1-LMP plus MVA-IiE1 
treatment (Figure 4E). The survival rate of heterologously vacci-
nated animals was increased to approximately 75% (Figure 4F). 
During the therapeutic challenge, we found no difference between 
standard and inverse αDEC-E1 plus Adeno–E1-LMP, which could 
suggest that early CD8+ T cell responses are of similar importance 
to sustained CD8+ T cell responses upon CD4+ T cell help. Another 
hypothesis to explain this phenomenon would be that the tumor 
may have already primed T cell responses, and therefore priming 
by DEC205 targeting would be less effective than in the preventive 
setting. Interestingly, homologous vaccinations had only a mild 
effect on tumor growth and survival in the therapeutic setting. 
However, the spread of EL4-E1 tumor cells into LNs during the 
therapeutic challenge was prevented only with Adeno–E1-LMP 
plus MVA-IiE1 vaccination (Figure 4G). Thus, both αDEC-E1 plus 
Adeno–E1-LMP and Adeno–E1-LMP plus MVA-IiE1 vaccinations 
performed best as prophylactic or therapeutic treatments during 
EL4-E1 challenge.
Dependence on CD4+ and CD8+ T cell populations for protection 
from EL4-E1 challenge after heterologous vaccination. To understand 
the dependence of the αDEC-E1 plus Adeno–E1-LMP and Adeno–
E1-LMP plus MVA-IiE1 heterologous prime-boost vaccine formu-
lations on CD4+ and CD8+ T cell populations for protection from 
EL4-E1 challenge, either CD4+ or CD8+ T cells were depleted with 
Abs on 3 consecutive days before the prime and the boost. Two 
weeks after the boost, 2 × 105 EL4-E1 cells were injected s.c. and 
measured every second day by caliper (Figure 5A). We confirmed 
complete T cell depletion in blood on the day of the prime and the 
boost and also observed a substantial decrease in the respective 
T cell populations of splenic cells, even around 45 days after the 
last depleting Ab injection (Supplemental Figure 3C). Notably, the 
T cell–depleted mice in the PBS treatment group did not show a 
significant difference of EL4-E1 tumor growth kinetics compared 
with the nondepleted animals (Figure 5B). When we compared 
Figure 6. Protection from EBNA1-induced B cell lymphoma challenge by 
heterologous vaccination. (A) huDEC205-Tg mice were immunized with 
different combinations of vaccines for the prime and the boost, sched-
uled 10 days apart. Mice were challenged with 3 × 106 to 5 × 106 EBNA1+ B 
cell tumor cells (BL-E1) i.v. 14 days after the boost in a preventive setting. 
Mice were monitored every second day, including measurement of weight, 
observation of general behavior, and assessment using the mouse grimace 
scale. (B) At sacrifice, bulk single-cell suspensions of cells from LNs, 
spleen, liver, and blood were harvested and analyzed by EBNA1 qPCR. 
Abundance of the EBNA1 gene was normalized to the UBC gene as the 
tumor load. Data are shown as the mean ± SD from 2 independent exper-
iments with at least 5 mice per group. (C) A tumor load cutoff of 0.005 or 
higher was set, and results of all analyzed organs from each mouse were 
pooled. The percentage of mice per condition without tumor burden and 
with tumor burden in 1 to 4 organs is depicted. *P < 0.05; Mantel-Cox test. 
(D) At sacrifice, splenic tissue from treated mice with EBNA1-induced B cell 
lymphoma were fixed in PFA and embedded in paraffin. Splenic tissues 
from PBS-treated mice without tumor treatment were used. Splenic tissue 
samples were stained with H&E, αCD19, αPCNA, and αXIAP Abs. One rep-
resentative staining for each group is shown. Scale bar: 20 μm.
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Figure 7. Characteristics of T cell responses toward EBNA1-induced B cell lymphomas with and without protective vaccination. huDEC205-Tg mice were immu-
nized with different combinations of vaccines for the prime and the boost, scheduled 10 days apart. Mice in the preventive group were challenged i.v. with 3 × 106 
to 5 × 106 BL-E1 tumor cells 14 days after the boost. (A) At sacrifice, bulk splenocytes were harvested and stimulated with 1 μg/ml EBNA1 or control HCMV pp65 
peptide pools. IFN-γ production was monitored by ICS in CD4+ gated cells. Data are shown as the mean ± SEM from 2 independent experiments with at least 5 
mice per group. Statistical analyses was done using a 2-tailed Mann-Whitney U test. (B) After splenocyte stimulation, IFN-γ production was monitored by ICS in 
CD8+ gated cells. Data are shown as the mean ± SEM from 2 independent experiments with at least 5 mice per group. **P < 0.01 and ***P < 0.001; Kruskal-Wallis 
with Dunn’s multiple comparisons test (C) The CD4+/CD8+ T cell ratio was calculated using the percentages of each subset in the spleen. *P < 0.05; 1-way ANOVA 
with Tukey’s multiple comparisons test. (D) At sacrifice, bulk splenocytes were harvested and stained for PD-1 on CD8+ gated cells. Total PD-1+CD8+ cell amounts 
per spleen were calculated using the total splenocytes count. Data are shown as the mean ± SEM from 2 independent experiments with at least 5 mice per group. 
Mice with PBS treatment or vaccination and tumor injection were compared with mice that were only treated with PBS or vaccinated. **P < 0.01; Kruskal-Wallis 
with Dunn’s multiple comparisons test. (E) Splenic tissue was fixed in PFA and embedded in paraffin and then stained with H&E, αCD8, and αCD4. One represen-
tative image from each group is shown, along with an image of splenic cells from a PBS-treated mouse without tumor challenge. Scale bar: 20 μm.
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mice compared with the percentage in PBS-treated mice (Figure 
7A). However, the percentage of EBNA1-specific IFN-γ–secreting 
CD8+ T cells was significantly enhanced after Adeno–E1-LMP 
plus MVA-IiE1 vaccination (Figure 7B). Curiously, αDEC-E1 plus 
Adeno–E1-LMP vaccination led to only a modest increase in 
EBNA1-specific CD8+ T cells. In recent studies, it was shown that 
mice with primary BL-E1 tumors had an imbalanced CD4+/CD8+ 
T cell ratio in the spleen, which was lower compared with mice 
without tumors (36). We observed a slight decrease of both CD4+ 
and CD8+ T cells in tumor-bearing spleens compared with spleens 
in tumor-free mice, and this was most visible in the PBS-treated 
mice (Supplemental Figure 4B). The different levels of CD4+ and 
CD8+ T cells in the T cell compartments were also observed in the 
ratio of CD4+ to CD8+ T cells, which was significantly decreased 
in the PBS-treated group (Figure 7C). The inability of CD8+ T cells 
to respond to EBNA1 antigen restimulation in the  group of mice 
vaccinated with αDEC-E1 plus Adeno–E1-LMP raised the question 
of whether those T cells showed upregulation of programmed cell 
death protein 1 (PD-1), which is known to play a role in attenuating 
tumor immunity in many different types of cancers. Indeed, PD-1 
levels were substantially increased on splenic CD8+ T cells from 
PBS-treated mice that underwent tumor cell injection compared 
with levels in healthy mice (Figure 7D). PD-1 expression on CD8+ 
T cells after αDEC-E1 plus Adeno–E1-LMP vaccination reached 
an intermediate level, which was significantly lower than that in 
the tumor-bearing PBS-treated animals. Animals vaccinated with 
Adeno–E1-LMP plus MVA-IiE1 had very low PD-1 expression 
levels in their splenic CD8+ T cell compartment, independent of 
tumor cell injection. In order to examine the distribution of T cells 
in the affected organs, splenic sections were stained with H&E 
and αCD4 and αCD8 Abs (Figure 7E). Although most mice that 
were both PBS treated and tumor challenged showed disruption 
of the white pulp and T cell zones, αDEC-E1 plus Adeno–E1-LMP 
vaccination could attenuate this phenotype, leading to small T cell 
zones and differentiation of white and red pulp in some areas. In 
contrast, most mice in the Adeno–E1-LMP plus MVA-IiE1 vacci-
nation group had spleens with a healthy phenotype, sharp sepa-
ration of red and white pulp, and large T cell zones, all of which 
were observed in PBS-treated mice without tumor challenge. Liv-
er sections from PBS-treated mice confirmed these alterations 
after BL-E1 tumor establishment, which led to high lymphocyte 
infiltration and structural damage in the livers of tumor-bearing 
mice (Supplemental Figure 4C). Whereas αDEC-E1 plus Adeno–
E1-LMP seemed to have a similarly strong effect on EBNA1+ T 
cell lymphomas, these findings suggest that Adeno–E1-LMP plus 
MVA-IiE1 vaccination might be much more suitable for preventing 
EBV-associated B cell malignancies.
Discussion
Our study identifies heterologous prime-boost regimens of pref-
erentially CD4+ and CD8+ T cell–priming vaccine formulations 
as superior immunization strategies to expand EBNA1-specif-
ic CD4+ and CD8+ T cell responses, with EBNA1-expressing 
adenovirus boosted by MVA vaccination being the most prom-
ising approach. These provide protection against EBV anti-
gen–expressing T and B cell lymphomas, the latter of which 
spontaneously originated from Tg EBNA1 expression in murine 
B lymphoma cells (BL-E1) occur spontaneously in the LNs and 
spleens of EμEBNA1-Tg mice (37) and show relatively low EBNA1 
expression, which can be visualized by Western blotting but not 
IHC (Supplemental Figure 4A). BL-E1 tumor cells overexpress the 
c-Myc proto-oncogene, as do Burkitt’s lymphomas. Tumorigene-
sis was found to be unequivocally linked to EBNA1 expression and 
dependent not only on c-Myc but on Mdm2 deregulation as well 
(36). To evaluate the protective value of the vaccinations against 
these EBNA1-induced B cell lymphomas, 3 × 106 to 5 × 106 CD19+ 
B cells isolated from the spleens of tumor-bearing EμEBNA1-Tg 
mice were injected i.v. 14 days after the boost. The mice were euth-
anized at the latest 45 days after tumor cell injection or when they 
showed signs of sickness such as weight loss or reduced activity 
(Figure 6A). At sacrifice, DNA from the spleen, blood, LNs, and 
liver was isolated and analyzed for EBNA1 DNA levels (Figure 
6B). Following Adeno–E1-LMP plus MVA-IiE1 vaccination, we 
found that the amount of EBNA1 DNA was lower in all analyzed 
organs when compared with levels in PBS-treated mice, whereas 
in the αDEC-E1 plus Adeno–E1-LMP group, the levels were similar 
to those in the PBS-treated control group. We evaluated the total 
tumor burden in each mouse using the detection limit of EBNA1 
DNA qPCR (Figure 6C). After Adeno–E1-LMP plus MVA-IiE1 vac-
cination, over half of the mice remained tumor free in all of the 
organs examined, whereas only 35% of the mice vaccinated with 
αDEC-E1 plus Adeno–E1-LMP were tumor free. Forty- five percent 
of the PBS-treated mice had BL-E1 metastasis in 3 or more of the 
analyzed organs, whereas none of the mice treated with Adeno–
E1-LMP plus MVA-IiE1 had metastasis in more than 2 organs. The 
phenotype of EBNA1-induced B cell lymphomas was studied pre-
viously (36). In our study, we confirmed that expression of XIAP 
and proliferating cell nuclear antigen (PCNA), a proliferation 
marker like Ki67, by IHC, and expression of EBNA1, by Western 
blotting, were strongly correlated with tumor pathology in the 
mice (Figure 6D and Supplemental Figure 4A). In vaccinated 
mice, only CD19hi-expressing cells with a more typical lymphocyte 
morphology could be found, which indicates that these cells are 
classical B cells. Following EBNA1+ tumor cell injection, CD19dim- 
expressing cells in PBS-treated mice accumulated with PCNA and 
XIAP expression compared with mice treated with αDEC-E1 plus 
Adeno–E1-LMP or Adeno–E1-LMP plus MVA-IiE1. The expres-
sion of XIAP was not unexpected, since it was shown that EBNA1 
tumorigenesis is dependent on Mdm2 signaling, which promotes 
XIAP translation (36). Taken together, we conclude that αDEC-E1 
plus Adeno–E1-LMP vaccination seems to lower the tumor bur-
den upon BL-E1 injection, whereas Adeno–E1-LMP plus MVA-IiE1 
vaccination leads to a more effective reduction in tumor load, as 
indicated by the EBNA1 DNA load, spleen histology, and EBNA1- 
specific Western blot analysis.
Characteristics of T cell responses to EBNA1-induced B cell lym-
phomas with and without protective vaccination. In order to investi-
gate the different mechanisms of the vaccination strategies used 
to restrict EBNA1-induced B cell lymphomas, we further assessed 
T cell populations by FACS and histological analyses. At sacrifice, 
splenic cells were restimulated with EBNA1 and HCMV control 
peptide libraries, and CD4+ and CD8+ T cell responses were mea-
sured by IFN-γ secretion with ICS. We observed no difference 
in the percentage of IFN-γ–secreting CD4+ T cells in vaccinated 
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 0 8 4 jci.org   Volume 129   Number 5   May 2019
a robust antigen-specific CD8+ T cell response (Figure 2 and Fig-
ure 3). Moreover, the improved CD4+ and CD8+ T cell responses 
following heterologous prime-boost vaccination with αDEC-E1 
and Adeno–E1-LMP were translated into protection against EBV 
antigen–expressing lymphoma challenge.
In parallel to this development of heterologous prime-boost 
vaccinations with DC-targeted antigens, heterologous prime-
boost vaccinations with different viral vectors were devel-
oped. Originally designed to confer both CD8+ T cell–mediated 
immune control of the liver stage and CD4+ T cell–orchestrated 
immune suppression of the blood stage of malaria infection (57), 
heterologous adeno- and poxvirus vaccination was used in clini-
cal trials for malaria, Ebola, and influenza virus antigens (28, 58–
60). CD4+ T cell–dependent Ab production was mainly observed 
after poxvirus vaccination, whereas adenovirus-derived anti-
gen expression allowed for CD8+ T cell priming. This optimized 
CD4+ and CD8+ T cell vaccination regime reduced malaria infec-
tion by two-thirds in African adults (28) and established protec-
tion against EBV antigen–expressing T and B cell lymphomas 
in our study. Interestingly, αDEC-E1 plus Adeno–E1-LMP had 
protective efficacy against T cell lymphoma that was equivalent 
to that of Adeno-E1 plus MVA-IiE1 vaccination (Figure 4). Also, 
protein vaccines have the advantage of being more readily man-
ufactured, safe, and less expensive than viral vector vaccines. 
The 2 clinical settings in which such vaccination strategies could 
be tested include the treatment of EBV-seronegative adolescents 
with a 30%– 50% risk for developing infectious mononucleo-
sis upon primary EBV infection (61) and patients with EBV-as-
sociated lymphomas or carcinomas, the latter of which are the 
most frequent EBV-associated malignancies with currently lim-
ited therapeutic options (3). These vaccination strategies might 
be less useful in patients with EBV-associated lymphomas that 
emerge during immune suppression, as these lymphomas can 
be successfully targeted by adoptive EBV-specific T cell transfer 
(11). Thus, we plan to further develop heterologous αDEC-E1 plus 
Adeno–E1-LMP and heterologous Adeno-E1 plus MVA-IiE1 vac-
cination strategies in order to improve therapeutic vaccination 
for patients with EBV-associated tumors as well as prophylactic 
vaccination to prevent the symptomatic primary EBV infection 
that leads to infectious mononucleosis.
Methods
αDEC205-EBNA1 and other EBNA1-Ab fusion proteins. αDEC205-EB-
NA1 fusion Abs were produced by transient transfection (calcium chlo-
ride) of human HEK293T cells. The fusion Abs were tested for binding 
as described previously (21). All other EBNA1-Ab fusion proteins were 
designed and produced in collaboration with Miltenyi Biotec. Abs 
were produced in stably transfected, nonadherent HEK293T cell lines 
and were purified using Protein L columns (GE Healthcare) for a first 
purification and high-performance HisTrap Nickel-NTA columns (GE 
Healthcare) for a second purification step. Dialysis was performed 
overnight in 1 liter of 1× PBS using dialysis tubing from Spectrum Labs 
(3.5 kDa molecular weight cutoff [MWCO]; Thermo Fisher Scientific). 
Characterization was done by SDS-PAGE followed by Western blot-
ting with rat αEBNA1 primary Ab (clone 1H4), which was provided by 
Friedrich Grässer (62). Binding assays were performed with increasing 
concentrations of competitive pure Abs of the same clonal specificity. 
B cells and share some similarities with EBV-associated B cell 
lymphomas in humans, primarily latency I Burkitt’s lymphomas 
(36, 37). Therefore, EBNA1-based heterologous prime-boost vac-
cinations should be further developed as therapeutic strategies 
against EBV-associated malignancies.
In contrast, homologous vaccinations with EBNA1-encod-
ing recombinant viral vectors have already been attempted in 
patients with nasopharyngeal carcinoma (38, 39). In these studies, 
a recombinant MVA vector was used that encodes both EBNA1 
and LMP2 and is capable of expanding specific CD4+ and CD8+ 
T cells in response to these 2 viral antigens in vitro (25). Intrader-
mal injection of this vaccine candidate increased EBNA1- and/or 
LMP2-specific T cell responses in 15 of 18 treated Chinese and in 
8 of 14 British patients with nasopharyngeal carcinoma (38, 39). 
Furthermore, this vaccination increased the proportion of these 2 
viral antigen–specific T cells, which produced TNF-α, IFN-γ, and/
or IL-2, suggesting the functional superiority of these T cells (39). 
In parallel, in another study, a recombinant adenoviral vector 
encoding EBNA1 and HLA-A2–restricted polyepitopes of LMP1 
and LMP2 was explored (40). In vitro stimulation with this vaccine 
formulation reversed the functional impairment of EBV-specific 
CD8+ T cells from patients with Hodgkin’s lymphoma (26). More-
over, in vitro expansion of EBNA1- and LMP-specific T cells in vitro 
and adoptive transfer into patients with nasopharyngeal carcino-
ma after primary tumor resection more than doubled the patients’ 
median overall survival (41). As in our mouse model, a balanced 
expansion of EBV-specific CD4+ and CD8+ T cell responses was 
suggested to be important for these clinical effects. Previous stud-
ies in patients with nasopharyngeal carcinoma showed that only 
transiently expanded CD8+ T cells with LMP2 peptide–loaded or 
LMP1- as well as LMP2-encoding adenovirus–infected DCs led to 
partial clinical responses in only 2 of 16 and 1 of 12 of the patients 
(42–44). We explored new vaccination strategies, and our find-
ings suggest that improved CD4+ and CD8+ T cell–mediated EBV 
immune control might be achieved by heterologous prime-boost 
vaccinations with EBNA1 as the protective EBV antigen.
Heterologous prime-boost vaccination strategies combine 
different antigen delivery systems to improve immune respons-
es. Our in vitro studies compared targeting of 8 different surface 
receptors using EBNA1-specific CD4+ and CD8+ T cell clones as 
the readout for the efficiency of antigen presentation in PBMCs. 
DEC205 remains one of the most efficient targeted receptors 
for stimulating T cell responses (Figure 1). This is consistent 
with other studies using different methods to assess the level of 
antigen presentation (45). However, vaccination by antigen tar-
geting to the DC receptor DEC205 elicits, with the exception of 
hen egg–derived model antigens, mostly CD4+ T cell responses 
in vivo (21, 22, 46–54). This CD4+ T cell bias also led to only mod-
est efficacy after DEC205-targeted NY-ESO1 vaccination, with 
tumor regression seen in only 2 of 45 patients (55). These CD4+ 
T cell responses could, however, be complemented with CD8+ T 
cell responses by a heterologous poxvirus–based vaccination for 
HIV gag p24 in nonhuman primates (56). Expanding on this pre-
vious study further, we compared the boosting of 3 different viral 
vectors after priming with DEC205 and showed that priming 
with DEC205 targeting and boosting with either adenoviral or 
lentiviral vector vaccines, but not boosting with MVA, resulted in 
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duplicates by coculturing autologous EBNA1-loaded PBMCs (5 × 
104/well) overnight with T cell clones (5 × 103/well) in 96-well V-bot-
tomed plates. IFN-γ released into the supernatant was measured by 
IFN-γ ELISA (Mabtech).
αEBNA1 IgG ELISA. The αEBNA1 IgG titer was acquired from 
serum samples at the point of sacrifice or from plasma acquired during 
bleeding procedures using the EBNA IgG ELISA kit (Bio-Rad) with goat 
α-mouse–HRP conjugate diluted 1:2000 in PBS. The OD was measured 
at 450 nm by the TECAN Infinite M200 Pro microplate reader.
EBNA1 copy quantification by qPCR. DNA from single-cell suspen-
sions of cells from blood, spleen, liver, and LNs was isolated using a 
DNA isolation kit (QIAGEN). qPCR was performed using 25 ng of each 
sample in triplicates with the TaqMan Universal PCR kit from Applied 
Biosystems. The probe 5′-/56-FAM/AGGAACTGC/ZEN/CCTTGC-
TATTCCACA/3IBkFQ/-3′, primer 5′-GGAGACGACTCAATG-
GTGTAAG-3′ and 5′-GGTGTGTTCGTATATGGAGGTAG-3′ from 
Integrated DNA Technologies was used for EBNA1 qPCR. EBNA1 
abundance was normalized to the UBC housekeeping gene with probe 
5′-/56-FAM/CGAGCCCAG/ZEN/TGACACCATTGAGAA/3IBk-
FQ/-3′, primer 5′-CCTCCTTGTCCTGGATCTTTG-3′, and 5′-AGGT-
GGGATGCAGATCTTTG-3′.
Histology. Tissue was fixed using 4% formalin and then embed-
ded in paraffin. Histological stainings were performed by Sophisto-
lab. For IHC, 3-μm sections were processed on a Leica BOND-MAX 
or Bond-III automated IHC system. Stainings were performed with 
monoclonal rat α–mouse CD19 (clone 60MP31, Invitrogen, Thermo 
Fisher Scientific), rat α–mouse CD4 (clone 4SM94, eBioscience), rat 
α–mouse CD8 (clone 4SM15, eBioscience), rat αFoxP3 (clone EP340, 
Clinisciences), and αPCNA (clone PC10, BioLegend). EBNA1-specific 
IHC was performed with the 1H4 Ab as previously described (64).
In vivo immunization. Mice were injected i.p. with 5 μg α–mouse 
DEC205 fused with EBNA1 mAb with 50 μg poly(I:C)-LMW (Invivo-
Gen) as an adjuvant (21) or i.v. with viral vectors at different infectious 
units. The adenoviral vector was administered at 109 PFU/mouse (40), 
whereas all other viral vectors were injected at 1.5 × 107 TU/mouse. 
The immunization was boosted 10–14 days later with the same dose of 
αDEC205-E1/poly(I:C) or a viral vector. One week after the boost, the 
mice were sacrificed, and bulk splenocytes were isolated for analysis.
In vivo T cell depletion. T cell depletion was done by injections of 200 
μg αCD4 mAb (GK1.5) or αCD8 mAb (2.43) (commercially available 
from Bio X Cell) on 3 consecutive days before the prime and the boost.
Statistics. Statistical analysis was performed using 1-way ANOVA 
with Bonferroni’s pre-test, 2-way ANOVA with Tukey’s multiple com-
parisons test, Kruskal-Wallis with Dunn’s post test, Mantel-Cox, or 
2-tailed Mann-Whitney U test. P values below 0.05 were considered 
statistically significant.
Study approval. All animal protocols were approved by the can-
tonal veterinary office of the canton of Zurich, Switzerland (protocols 
209/2014 and 159/2017). All studies involving human samples were 
reviewed and approved by the cantonal ethics committee of Zurich, 
Switzerland (protocol KEK-StV-Nr.19/08).
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For the Ab fusion proteins, the following clones srom Miltenyi Biotec 
were used: BDCA1 (AD5-8E7), BDCA3 (AD5-14H12), CD40 (HB14), 
CD11c (MJ4-27G12), CD206 (DCN228), CD207 (MB22-9F5), HLA-
DR (AC122), and DEC205 (MG38.2).
Viral vectors. The Adeno–E1-LMP recombinant adenoviral vec-
tor used in this study carries an EBNA1-LMP-polyepitope insert, 
which is incorporated into the replication-deficient mammalian 
vector Ad5F35, as previously described (26). The MVA is an attenu-
ated vaccinia virus that has been used for smallpox vaccination (63). 
The MVA vector pSC11 carried a fusion protein insert of the Gly/
Ala repeat–deleted EBNA1, either with Ii (MVA-IiE1) or without it 
(MVA-E1) (25). MVA-IiE1 and MVA-E1 viruses were produced as pre-
viously described (25). Additionally, we used a replication-impaired 
lentivirus carrying EBNA1 with and without the invariant chain (Ii) 
in a pHR-SIN-CSGWDNotI (pCSGW) backbone with an IRES-GFP-
tag (referred to herein as Lenti-E1 and Lenti-IiE1), together with the 
2 helper plasmids pMDG and pCMVDR8.91 (p8.9) (64). The invariant 
chain functions as a guiding protein for the EBNA1 protein and targets 
EBNA1 for the endolysosomal pathway for degradation. This facili-
tates the processing of EBNA1 and subsequent presentation on MHC 
class II. To produce Lenti-E1 and Lenti-IiE1, 107 HEK293T cells were 
transfected with the 20 μg of the plasmid of interest and the 2 lenti-
viral packaging plasmids (10 μg pMDG and 20 μg p8.9) using transient 
transfection with calcium chloride. Approximately 30 to 32 hours after 
medium exchange, the virus was harvested. The viral supernatant was 
collected, centrifuged, filtered, and purified using the Vivapure Lenti-
SELECT 40 kit (Sartorius) according to the manufacturer’s protocol. 
The purified virus was eluted into cold PBS, aliquoted, and stored at 
–80°C. Lenti-E1 and Lenti-IiE1 were titrated on HEK293T cells and 
incubated for 2 days. The amount of infected cells was quantified by 
GFP expression using a FACSCanto II system (BD Biosciences). The 
concentration of transfection units per milliliter (TU/ml) was calculat-
ed using the following formula: (% infected cells × cells used in the 
titration/100 × 1000 μl/μl virus added to the well) = TU/ml.
Tumor models. EL4 cells were provided by Melanie Greter (Uni-
versity of Zurich). These EL4 cells were infected by Lenti-E1 GFP, 
single-cell sorted with a FACSAria III 5L at the University of Zurich 
Cytometry Core Facility, and reached a purity of 98% GFP+ cells. 
EBNA1+ B lymphoma cells were harvested as previously described 
(36, 37). Both cell lines were analyzed by Western blotting for EBNA1 
expression using rat αEBNA1 primary Ab (clone 1H4, provided by Frie-
drich Grässer [ref. 62]; diluted 1:50 in PBS).
huDEC205-Tg mice. huDEC205-Tg C57BL/6 mice were a gift 
from Cheolho Cheong (IRCM, Montreal, Canada) and were bred 
at 8 to 12 weeks of age at the local animal facility of the University 
of Zurich. Maintenance of the huDEC205 transgene was controlled 
by PCR for each mouse using the forward primer 5′-TGGAAGAGA-
CATGGAGAAACCT-3′ and reverse primer 5′-TCTCAGGCCAGTC-
CAGAAGTA-3′.
T cell assays. PBMCs were obtained from whole blood of donors 
after red blood cell removal by density gradient centrifugation using 
Ficoll-Paque (GE Healthcare) following the manufacturer’s instruc-
tions. PBMCs were either incubated for 4 hours with 1 μg/ml EBNA1 
fusion Abs or DMSO control or were infected with viral vectors at a 
MOI of 10 for 24, 48, 72, and 96 hours. As a positive control, PBMCs 
were incubated with 5 μM cognate peptide for 1 hour. PBMCs were 
washed extensively with PBS and T cell assays were performed in 
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